Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on April 11, 2025. The filing addresses a corporate governance event regarding the appointment of an interim executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Barry K. Brown as interim principal financial officer, effective April 11, 2025. Mr. Brown, who has served as the Company's chief accounting officer since March 2022 and previously as interim principal financial officer from March 2022 to December 2022, will continue to receive his current annual salary of $231,000 during this interim period.
Guidance, Outlook, and Management Commentary
- Search for Permanent CFO: The Company is actively conducting an external search process to identify a permanent chief financial officer to serve as the principal financial officer.
- Compensation: No change in compensation was made for Mr. Brown's interim role; he retains his existing salary.
- Risks and Contingencies: The filing states there are no family relationships between Mr. Brown and any director or executive officer, and no reportable transactions under Item 404(a) of Regulation S-K exist.
Important Facts for Investor Verification
- Barry K. Brown is serving as interim principal financial officer effective April 11, 2025.
- The Company is currently searching for a permanent chief financial officer.
- Mr. Brown's interim compensation remains at $231,000 per year.
- This filing contains no financial performance data or updated guidance.